Drug Profile


Alternative Names: Aoquqing; BTS 54524; Ectiva; KES 524; Meridia; Reductase; Reductil; Reduxade; Sibutral

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Abbott GmbH & Co. KG
  • Developer Abbott GmbH & Co. KG; AstraZeneca; Eisai Co Ltd; Il Sung; Nanjing Chang'ao Pharmaceutical
  • Class Anorectics; Cyclobutanes; Obesity therapies
  • Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Obesity
  • Discontinued Major depressive disorder

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 24 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
  • 28 Oct 2010 Discontinued - Preregistration for Obesity in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top